The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma

Elin Ødegaard, Anne Cathrine Staff, Vera M. Abeler, Juri Kopolovic, Mathias Onsrud, Philip Lazarovici, Ben Davidson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

The objective of this study was to compare the expression of the nerve growth factor (NGF) receptors TrkA and p75 in ovarian borderline tumors, International Federation of Gynecology and Obstetrics (FIGO) stage I carcinomas and advanced-stage (FIGO stage III-IV) carcinomas, and to assess a possible association between NGF receptor expression and mitogen-activated protein kinase (MAPK) activation in borderline tumors and FIGO stage I carcinomas. Sections from 119 borderline tumors, 57 FIGO stage I invasive ovarian carcinomas, and 56 advanced-stage carcinomas were evaluated for expression of activated phospho-TrkA (p-TrkA) and p75 using immunohistochemistry. MAPK activation was analyzed in stage I carcinomas and borderline tumors using phospho-specific antibodies against the extracellular-regulated kinase (p-ERK), the high osmolarity glycerol response kinase (p-p38), and the c-jun amino-terminal kinase (p-JNK). p-TrkA membrane expression was significantly more frequent in advanced-stage carcinomas compared with both borderline and stage I carcinomas (P < .001). p75 membrane expression was comparable in the 3 groups (P > .05). p-ERK and p-p38 expression was comparable in borderline and stage I carcinomas, whereas p-JNK was more frequently expressed in stage I ovarian carcinomas (P < .001). NGF receptor expression showed no association with MAPK activation in borderline and stage I carcinomas. In conclusion, expression of biologically active p-TrkA receptor at the cell membrane is up-regulated along tumor progression in ovarian carcinoma, whereas p75 expression remains unaltered. These data provide further evidence regarding the clinical role of p-TrkA in ovarian carcinoma. NGF receptors probably signal via MAPK-independent pathways in ovarian carcinoma.

Original languageEnglish
Pages (from-to)140-146
Number of pages7
JournalHuman Pathology
Volume38
Issue number1
DOIs
StatePublished - Jan 2007

Keywords

  • Mitogen-activated protein kinases
  • Nerve growth factor receptor
  • Ovarian carcinoma

Fingerprint

Dive into the research topics of 'The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma'. Together they form a unique fingerprint.

Cite this